Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13653689 | 0.90 | KMT2A (0.44) | HDAC1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL11885453 | 0.90 | HDAC1 (0.49) | HDAC1KMT2AMEN1L3MBTL1CFTR | |
| SCHEMBL11885454 | 0.90 | HDAC1 (0.56) | HDAC1KMT2AMEN1L3MBTL1CFTR | |
| SCHEMBL4122547 | 0.89 | KMT2A (0.56) | HDAC1KMT2AMEN1L3MBTL1CFTR | |
| SCHEMBL11885458 | 0.88 | ELOVL1 (0.49) | HDAC1KMT2AMEN1L3MBTL1CFTR | |
| SCHEMBL4120494 | 0.88 | LMNA (0.52) | HDAC1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL1071240 | 0.87 | CFTR (0.62) | CFTRMAPTNPC1RAB9ATP53 | |
| SCHEMBL4109791 | 0.86 | HDAC1 (0.46) | HDAC1KMT2AMEN1L3MBTL1CFTR | |
| SCHEMBL4122625 | 0.85 | KMT2A (0.48) | HDAC1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL4123373 | 0.85 | CFTR (0.51) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980077-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2980077-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2980077-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2615085-B1 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130317020-A1 | Pyridyl Derivatives as CFTR Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2271621-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8524910-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2615085-A1 | Pyridyl derivatives as CFTR modulators | Vertex Pharmaceuticals Incorporated (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | HDAC1 3182/4885KMT2A 4636/4885MEN1 4857/4885 |
| US-20130317020-A1 | Pyridyl Derivatives as CFTR Modulators | CFTR, ABCC4, ABCB1 | HDAC1 3182/4885KMT2A 4636/4885MEN1 4857/4885 |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | HDAC1 3182/4885KMT2A 4636/4885MEN1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.